FDA Issues Sweeping Recall on Store-Brand Eye Drops

The U.S. Food and Drug Administration announced on April 4, 2026, one of the largest over-the-counter eye care recalls in recent memory, affecting approximately 3 million bottles of artificial tears and lubricant eye drops sold under store-brand labels at three of the nations largest pharmacy chains: CVS Health, Walgreens, and Rite Aid.

The recall, classified as Class II by the FDA, was initiated after routine testing identified potential microbial contamination in multiple production lots manufactured at a shared facility in New Jersey. While no confirmed infections have been reported to date, the agency emphasized that contaminated eye drops pose a serious risk, particularly to immunocompromised individuals and those with pre-existing eye conditions.

Which Products Are Affected?

The recall covers the following store-brand products:

“We are taking swift action to remove these products from shelves and notify consumers. Patient safety is our top priority.” — Dr. Sarah Chen, FDA Deputy Commissioner for Regulatory Affairs

What Caused the Contamination?

Preliminary investigations point to a compromised sterility barrier at the EyePharma Solutions manufacturing plant in Edison, New Jersey. The facility, which produces private-label eye care products for multiple retail chains, reportedly experienced an HVAC system failure in its clean room during a three-week window in January 2026.

FDA investigators found traces of Pseudomonas aeruginosa and Burkholderia cepacia complex in environmental samples taken from production areas. Both bacteria can cause severe eye infections, and in rare cases, Pseudomonas infections can lead to vision loss if untreated.

Consumer Safety Instructions

The FDA is advising consumers to take the following steps:

Retailer Response

All three pharmacy chains have begun pulling affected products from shelves nationwide. CVS Health issued a statement confirming that approximately 1.4 million bottles were distributed through its stores, while Walgreens accounts for roughly 1.1 million units and Rite Aid for 500,000 units.

CVS spokesperson Michael Torres stated that the company is “working closely with the FDA and the manufacturer to ensure a thorough recall process.” Walgreens and Rite Aid issued similar statements expressing commitment to customer safety.

Historical Context

This recall comes roughly three years after the 2023 eye drop contamination crisis that killed four people and left others permanently blind, prompting the FDA to significantly tighten oversight of ophthalmic product manufacturing. The agency implemented new sterility testing requirements in 2024, which contributed to the earlier detection of the current contamination.

Industry analysts note that the shared-manufacturing model used by major pharmacy chains creates concentration risk. When a single facility produces eye drops for multiple brands, a single contamination event can have cascading effects across the retail landscape.

What Happens Next

The FDA has dispatched a full inspection team to the Edison facility and stated that production will remain halted until corrective actions are verified. EyePharma Solutions faces potential enforcement action depending on the investigations findings.

Consumers seeking alternatives should look for name-brand products such as Refresh Tears, Systane, or GenTeal, which are manufactured at separate facilities unaffected by this recall. Those with ongoing eye conditions should consult their healthcare provider for guidance on substitute products.